Cargando…
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Several mutations conferring protection against Alzheimer's disease (AD) have been described, none as profound as the A673T mutation, where carriers are four times less likely to get AD compared to noncarriers. This mutation results in reduced amyloid beta (Aβ) protein production in vitro and l...
Autores principales: | Limegrover, Colleen S., LeVine, Harry, Izzo, Nicholas J., Yurko, Raymond, Mozzoni, Kelsie, Rehak, Courtney, Sadlek, Kelsey, Safferstein, Hank, Catalano, Susan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246829/ https://www.ncbi.nlm.nih.gov/pubmed/33025581 http://dx.doi.org/10.1111/jnc.15212 |
Ejemplares similares
-
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein
por: Limegrover, Colleen S., et al.
Publicado: (2021) -
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity
por: Izzo, Nicholas J., et al.
Publicado: (2014) -
Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery
por: LaBarbera, Kelsie Mozzoni, et al.
Publicado: (2021) -
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
por: Izzo, Nicholas J., et al.
Publicado: (2014) -
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021)